Table 1.
Baseline characteristics of enrolled participants.
| Placebo (N = 50) | N-acetylcysteine (N = 23) | P value | |
|---|---|---|---|
| Age, years (mean ± SD) | 70 ± 5 | 71 ± 4 | 0.13 |
| Sex, M/F | 27/23 | 26/24 | 0.84 |
| FEV1 (L), mean ± SD | 1.15 ± 0.31 | 1.06 ± 0.23 | 0.11 |
| SGQR (mean ± SD) | |||
| Symptoms | 70.5 ± 10.8 | 55.3 ± 10.7 | <0.01 |
| Activity | 69.4 ± 13.4 | 69.9 ± 10.4 | 0.83 |
| Impacts | 43.8 ± 13.8 | 36.7 ± 11.9 | <0.01 |
| Total | 55.7 ± 12.4 | 50.8 ± 9.5 | 0.03 |
| CBSAS (mean ± SD) | 2.2 ± 0.5 | 18.1 ± 4.2 | <0.01 |
| SF-36 (mean ± SD) | |||
| Physical | 37.1 ± 4.4 | 37.2 ± 3.9 | 0.91 |
| Mental | 49.6 ± 6.6 | 49.1 ± 7.4 | 0.71 |
M/F: male/female; FEV1: forced expiratory volume in the first second; SGQR: St. George's Respiratory Questionnaire; Short Form-36 Health Survey.